20% patients carried the PTEN mutation in the high‐risk group (Figure 4A), Zhao et al had demonstrated that GBM with PTEN mutation induce more immunosuppressive TME and is resistant to anti‐PD‐1 therapy.27 This evidence concerns the gene PDCD1 and glioblastoma.